Asmanex: adverse event reports filed with FDA

4,808

reports as suspect product

0% of all reports · about 233 a year

8

reports, 12 months to June 2026

20 in the 12 months before

7.1%

marked serious by the reporter

77.7% across the class

0.2%

record death among outcomes, as reported

12 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Asmanex reports recording the termmedian drug in corticosteroid

1. No adverse eventno adverse event was reported60.1%2,890
2. Product quality issuea problem with the product itself56.2%2,701
3. Poor quality device used39.9%1,916
4. Drug dose omissiona dose was missed30.1%1,447
5. Device malfunctionthe device did not work properly23.1%1,109
6. Circumstance or information capable of leading to medication errora situation that could lead to a medication error10.7%513
7. Product dose omissiona dose was missed9.1%437
8. Dyspnoeashortness of breath8.9%426
9. Product dose omission issuea dose was missed8.1%390
10. Product container issuea problem with the container7.2%346
11. Incorrect dose administeredthe wrong dose was given6.4%309
12. Coughcough6.4%308
13. Asthmaasthma4%192
14. Drug ineffectivethe medicine did not work as expected3.1%150
15. Wheezingwheezing2.6%124
16. Wrong technique in device usage process2.5%119
17. Product use issuea problem in how the product was used2.3%109
18. Device difficult to usethe device was hard to use2.2%105
19. Product use in unapproved indicationused for a purpose not on the label2%98
20. Chest discomfortchest discomfort2%96
21. Malaisegeneral feeling of being unwell1.5%71
22. Poor quality product administered1.4%69
23. Productive cougha cough with phlegm1.3%61
24. Product availability issuethe product was not available1.2%59
25. Wrong technique in product usage processthe product was used in the wrong way1.2%58
26. Accidental exposure to product1.1%54
27. Adverse eventan unwanted medical event, type not specified1%50
28. Product taste abnormalthe product tasted odd1%48
29. Headachehead pain0.9%42
30. Pneumonialung infection0.9%41

Top 30 of 272 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 74 drugs in the corticosteroid class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 808,789 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 97.8% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 4,808 reports.

Drugs most often listed in the same reports

Other products listed in reports where Asmanex is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the corticosteroid class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Asmanex as a suspect or interacting product; reports listing it only as a concomitant medication (2,732) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.